Wednesday, July 8, 2026

Patent intelligence · US

US 10000753

Age-related macular degeneration treatment

granted A61PA61P27/02A61P9/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 13
Patent details — US 10000753

Quick answer

US 10000753 (Age-related macular degeneration treatment) is held by Benitec Biopharma Limited. Status: granted. Granted Jun 19, 2018. Expires Jun 14, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
23
CPC classes
A61P, A61P27/02, A61P9/00

More from Benitec Biopharma Limited

Related pharmaceutical patents in our USPTO index.

  1. US 11932852

    Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

    Benitec IP Holdings Inc. · Expires Mar 14, 2044

    granted
  2. US 11535851

    Reagents for treatment of hepatitis B virus (HBV) infection and use thereof

    Benitec IP Holdings Inc. · Expires Dec 22, 2042

    granted
  3. US 11234994

    Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

    Benitec Biopharma Limited · Expires Jan 27, 2042

    granted
  4. US 11142765

    Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

    Benitec IP Holdings Inc. · Expires Oct 7, 2041

    granted
  5. US 10898505

    Reagents for treatment of hepatitis B virus (HBV) infection and use thereof

    Benitec Biopharma Limited · Expires Jan 21, 2041

    granted
  6. US 9518260

    Pain treatment

    Benitec Biopharma Limited · Expires Dec 8, 2036

    granted
  7. US 9410154

    HBV treatment

    Benitec Biopharma Limited · Expires Aug 4, 2036

    granted

Frequently asked questions

What is US patent 10000753?

US 10000753 (Age-related macular degeneration treatment) is held by Benitec Biopharma Limited. Status: granted. Granted Jun 19, 2018. Expires Jun 14, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10000753?

Benitec Biopharma Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.

When does US 10000753 expire?

Our index shows an expiration date of Jun 14, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.